LENALIDOMIDE RETREATMENT IN A PATIENT WITH RELAPSED MULTIPLE MYELOMA WHO HAD PREVIOUSLY RESPONDED TO LENALIDOMIDE

Abstract

Treatment of multiple myeloma has advanced over the last decade, most notably with the introduction of highly effective novel drugs. It is now possible to aim for deep disease responses in a greater number of patients in an attempt to prolong remission duration and survival. Initially introduced in the relapsed setting, Lenalidomide, is now being increasingly incorporated into upfront treatment strategies, raising questions about the feasibility of 'retreatment' with this agent. We present the case of a refractory multiple myeloma (MM) patient, in whom described retreatment with Lenalidomide was used in combination with Dexamethasone after failure of the previous treatment modalities.

Keywords

• multiple myeloma
• lenalidomide
• salvage therapy
• sequencing
• IMiDs